TCL Archive Ramucirumab Improves Overall Survival, Progression-Free Survival in Phase III Trial October 26, 2012
TCL Archive In Brief: FDA commissioner Kessler To Resign, Says His Goals Were Accomplished November 29, 1996
TCL Archive Von Eschenbach takes leave of absence from NCI, resigns from C-Change board. Acting FDA commissioner’s drug approval strategy rooted in unproven science. Von Eschenbach told NCI deputies he might drop in on meetings. Who’s really in charge? October 7, 2005
